Page 1:
1. RHEUMATOID ARTHRITIS (RA)
2. JUVENILE IDIOPATHIC ARTHRITIS (JIA)
3. OSTEOARTHRITIS (OA)
4. POLYMYALGIA RHEUMATICA (PMR)
5. FIBROMYALGIA (FM)
Amber Herrick, MS, PA-C, DFAAPA
Clinical Medicine I
September 16, 2025 1

Page 2:
Lecture Objectives:
For each disorder, compare and contrast the clinical presentation
For each disorder, identify appropriate referrals and patient education
Rheumatoid Arthritis (RA):
‚ó¶ Define Rheumatoid Arthritis and summarize the underlying pathophysiology  
‚ó¶ Discuss the classic clinical presentation of RA and the joints most affected
‚ó¶ Describe the characteristic joint deformities often seen in established RA
‚ó¶ Define extraarticular manifestations and list common ones seen in RA
‚ó¶ Describe the characteristic radiologic findings for RA
‚ó¶ Identify the laboratory values used in the diagnostic evaluation of RA
‚ó¶ Discuss the management of RA and why DMARDs are used in the treatment for RA
Juvenile Idiopathic Arthritis (JIA):
‚ó¶ Compare and contrast the three subtypes of JIA and identify the unique features of each

Page 3:
Lecture Objectives, continued
Osteoarthritis (OA): 
‚ó¶ Define OA and summarize the pathophysiology
‚ó¶ Discuss the primary symptoms of OA and the joints most affected
‚ó¶ Describe the characteristic joint deformities that can be seen in established OA
‚ó¶ Describe the characteristic radiologic findings of OA
‚ó¶ Discuss the nonpharmacologic and pharmacologic treatment of OA
Polymyalgia Rheumatica (PMR):
‚ó¶ Describe the classic clinical presentation of PMR
‚ó¶ State the laboratory value most diagnostic of PMR
‚ó¶ State the recommended initial treatment for PMR
Fibromyalgia (FM):
‚ó¶ Describe the clinical manifestations and associated disorders often seen in with FM
‚ó¶ Discuss physical exam findings most consistent with FM
‚ó¶ Describe the stepwise approach to fibromyalgia therapy and state the initial therapy for most patients

Page 4:
Rheumatology:  
Terminology
‚ó¶ Articular = relating to a joint(s)
‚ó¶ Monoarticular, oligoarticular, polyarticular 
‚ó¶ Mono = one
‚ó¶ Oligo = few (or small)
‚ó¶ Poly = many
‚ó¶NSAIDs = nonsteroidal antiinflammatory drugs
‚ó¶Glucocorticoids = Corticosteroids = ‚Äústeroids‚Äù
‚ó¶DMARDs = disease modifying antirheumatic drugs

Page 5:
RHEUMATOID ARTHRITIS 
(RA)
News Medical Life Sciences

Page 6:
Rheumatoid Arthritis (RA): 
Overview 
‚ó¶ Chronic, systemic, autoimmune, inflammatory 
disease of unknown etiology 
‚ó¶ Primarily involves synovial joints
‚ó¶ Symmetrical polyarthritis is typical 
‚ó¶ Affects ~ 1 % of the population
‚ó¶ Women > Men (3:1 ratio)
‚ó¶ Peak onset is between 35 and 50 years
‚ó¶ Untreated, RA causes joint destruction
‚ó¶ In addition to affecting joints, RA can also have 
systemic extraarticular manifestations

Page 7:
Rheumatoid Arthritis:  
Pathogenesis
‚ó¶ Complex interaction between genes and 
environment!
‚ó¶ E.g., smoking, altered microbiome
‚ó¶ Leads to synovial inflammation (synovitis)
‚ó¶ The synovium organizes itself into an 
invasive tissue ‚Üí
‚ó¶ Can lead to erosion of bone, cartilage, 
ligaments, and tendon
7
ResearchGate.net; UpToDate
Normal RA

Page 8:
Rheumatoid Arthritis: 
Clinical Presentation
‚ó¶ Typically, a polyarticular disease
‚ó¶ Gradual onset is more common
‚ó¶ Progresses from periphery to proximal
‚ó¶ Small joints of the hands, wrists, and 
forefoot common in early disease
‚ó¶ Difficulty performing activities of daily 
living (ADL‚Äôs)
‚ó¶ Disease activity: natural exacerbations 
(‚Äúflares‚Äù) and reduced disease activity
‚ó¶ Constitutional symptoms may be 
present
‚ó¶ Myalgias, fatigue, low-grade fever, weight 
loss, poor sleep
8
Sarrica Physical Therapy

Page 9:
Rheumatoid Arthritis:
Commonly Affected Joints
‚ó¶PIP, MCP joints
‚ó¶ Spares the DIP joints
‚ó¶Wrists
‚ó¶MTP joints
‚ó¶Cervical spine

Page 10:
Rheumatoid 
Arthritis: 
Joint 
Symptoms 
Usually 
Predominate
10
‚ó¶ Joint pain, stiffness (especially morning 
stiffness), and symmetric swelling of many 
joints
‚ó¶ Morning stiffness > 1 hour
‚ó¶ Slowness or difficulty moving the joints 
when getting out of bed or;
‚ó¶ Stiffness after prolonged inactivity (gel 
phenomenon)
‚ó¶ Gets better with movement!

Page 11:
Hands:
Classic Findings of RA
‚ó¶MCP and PIP joints
‚ó¶ Symmetrical swelling of multiple 
joints with tenderness and pain
‚ó¶ Decreased ROM
‚ó¶ Inability to make a fist
‚ó¶ Reduced grip strength 
11
Synovitis bilaterally at multiple MCP joints in a 
patient with RA
Current Medical Diagnosis & Treatment, 2026

Page 12:
Hands: 
Characteristic Joint Deformities of RA
Appear in more established chronic RA
‚ó¶Swan neck
‚ó¶Boutonniere deformity
‚ó¶MCP subluxation
‚ó¶Ulnar deviation (‚Äúulnar drift‚Äù)

Page 13:
RHEUMATOID 
ARTHRITIS: 
ADDITIONAL MSK 
MANIFESTATIONS
‚Ä¢ W
rist
‚Ä¢ S
houlder
‚Ä¢ F
eet
‚Ä¢ K
nees
Joint Manifestation
Wrist
Carpal tunnel syndrome 
(synovitis of the wrist)
Elbow
Elbow synovitis (can result in a 
compressive neuropathy of 
ulnar nerve)
Shoulder ‚ÄúFrozen‚Äù shoulder
Knees Popliteal (Baker‚Äôs) cyst
Feet MTP joint tenderness
Cervical 
Spine
Atlantoaxial (C1-C2) subluxation 
can lead to myelopathy 
Not all-inclusive

Page 14:
EXTRAARTICULAR 
MANIFESTATIONS IN RA
‚Ä¢ Most have longstanding and severe, typically seropositive disease
‚Ä¢ Associated with increased overall morbidity, premature mortality

Page 15:
Extraarticular Manifestations in RA
15
System Manifestations
Skin Rheumatoid nodules
Eye Episcleritis/scleritis, uveitis, secondary Sj√∂gren syndrome (dry eyes/mouth)
Pulmonary Interstitial lung disease (ILD), pleuritis, pleural effusion
Cardiac CAD (accelerated atherosclerosis), heart failure, pericarditis
Vascular
Vasculitis
MSK Osteopenia/osteoporosis
Hematologic Felty syndrome: triad of RA, splenomegaly, and neutropenia
Renal Kidney disease
CNS Aseptic meningitis
Not all-inclusive

Page 16:
RHEUMATOID 
NODULES
EPISCLERITIS

Page 17:
RA: 
Differential 
Diagnosis
17
Infectious
Rheumatologic
‚Ä¢ Crystalline arthritis (gout/pseudogout)
‚Ä¢ Polymyalgia rheumatica
‚Ä¢ Reactive arthritis
‚Ä¢ Psoriatic arthritis
Noninflammatory
‚Ä¢ Osteoarthritis (OA)
‚Ä¢ Fibromyalgia

Page 18:
DIAGNOSTIC IMAGING
Radiography: preferred initial imaging study
MRI and Ultrasound: more sensitive at detecting changes 
(bone erosions) resulting from synovitis

Page 19:
Radiography: 
Characteristic Findings in RA:
‚ó¶Often normal in early disease
Progressive development of: 
‚ó¶ Soft tissue swelling
‚ó¶ Periarticular osteopenia
‚ó¶ Joint space narrowing
‚ó¶ Bony erosions (hallmark)
‚ó¶ Joint subluxation
19
UpToDate

Page 20:
RA:
SOFT TISSUE 
SWELLING AND 
MILD EROSIVE 
CHANGES

Page 21:
RA: 
ULNAR 
SUBLUXATION

Page 22:
LABORATORY TESTING

Page 23:
Laboratory 
Studies in RA
‚ó¶ Abnormal labs reflect the presence of 
systemic and intraarticular inflammation 
and the autoimmune features of RA. 
‚ó¶ Laboratory Tests: 
‚ó¶ Rheumatoid factor (RF)
‚ó¶ Anti-cyclic citrullinated peptide (anti-
CCP) antibodies 
‚ó¶ Antinuclear antibody (ANA)
‚ó¶ CBC
‚ó¶ ESR/CRP
‚ó¶ Synovial fluid analysis

Page 24:
Rheumatoid Factor & Anti-CCP Antibodies
24
RHEUMATOID FACTOR (RF) ANTI-CCP ANTIBODIES
75-80% of patients with RA test positive for RF, Anti-CCP antibodies (ACPA), or both
Improved sensitivity and specificity 
Presence of RF or Anti-CCP antibodies predicts poorer functional and radiographic 
outcomes
Order Both
ACPA = anti-citrullinated peptide antibodies (ELISA for antibodies against cyclic citrullinated peptides (CCP) is the most commonly used assay for ACPA)

Page 25:
Other Diagnostics Helpful 
in the Work-Up for RA
‚ó¶ ESR/CRP: elevated with active disease
‚ó¶ Often parallels the activity of the disease
‚ó¶ CBC
‚ó¶ May reveal indicators of inflammation
‚ó¶ Anemia of chronic disease, thrombocytosis, mild 
leukocytosis
‚ó¶ Arthrocentesis (removal of joint synovial fluid)
‚ó¶ Diagnosis or exclusion of gout, pseudogout, 
infection, etc. 
‚ó¶ Synovial fluid analysis
‚ó¶ Usually reveals an inflammatory effusion25
ESR = erythrocyte sedimentation rate (‚Äúsed rate‚Äù); CRP = C-reactive protein
Medscapestatic.com

Page 26:
26
*Of note: Seronegative RA (lack both RF 
and anti-CCP antibodies)
May be diagnosed based upon findings 
otherwise characteristic of RA if 
appropriate exclusions have been met
Don‚Äôt need to memorize

Page 27:
TREATMENT
272021 American College of Rheumatology Guidelines

Page 28:
RA: General 
Principles to 
Treatment
28
‚ó¶ Care by a Rheumatologist
‚ó¶ Goal: control synovitis/prevent joint injury
‚ó¶ Shared decision-making process
‚ó¶ Early use of DMARDs for all patients dx 
with RA
‚ó¶ Treat-to-target strategy: low disease 
activity or remission (see Resources 
section)
‚ó¶ Identification, management, and 
prevention of comorbid conditions that 
can complicate the disease course

Page 29:
Nonpharmacologic 
Treatment
29
Patient education 
Rest, exercise, PT/OT
Nutritional & dietary counseling
Psychosocial interventions 
Smoking cessation

Page 30:
RA:
Pharmacologic 
Treatment
30
‚Ä¢ Nonbiologic DMARDs
‚Ä¢ AKA: synthetic, traditional, or conventional 
‚Ä¢ Biologic DMARDs
‚Ä¢ TNF-inhibitors/Non-TNF-inhibitors
‚Ä¢ JAK inhibitor 
Disease Modifying 
Antirheumatic Drugs 
(DMARDs):
‚Ä¢ NSAIDs and/or Glucocorticoids
‚Ä¢ Used in an adjunctive role with DMARDs
Antiinflammatory Agents:

Page 31:
DMARDs: 
Disease 
Modifying 
Antirheumatic 
Drugs
‚ó¶ DMARDs slow/ halt disease progression, 
preserving joint function
‚ó¶ Risks include infection, malignancy, etc. 
‚ó¶ Requires pretreatment evaluation
‚ó¶ Baseline serology, TB test (before all 
biologic DMARDs and JAK inhibitors), 
vaccines

Page 32:
Nonbiologic 
DMARDs
32
Methotrexate
‚Ä¢ Generally recommended as initial 
therapy for most patients 
Others:
‚Ä¢ Sulfasalazine
‚Ä¢ Leflunomide
‚Ä¢ Hydroxychloroquine

Page 33:
Copyrights apply
FYI: 
DON‚ÄôT 
MEMORIZE
UpToDate

Page 34:
RA: Summary
‚ó¶Chronic synovitis
‚ó¶Polyarticular
‚ó¶Morning stiffness > 1 hr
‚ó¶ Swan neck/boutonniere 
deformity
‚ó¶ Extraarticular manifestations
‚ó¶X-ray: bony erosions
‚ó¶RF/anti-CCP antibodies
‚ó¶DMARDs (Methotrexate)

Page 35:
JUVENILE IDIOPATHIC 
ARTHRITIS
‚Ä¢ Systemic JIA
‚Ä¢ Oligoarticular JIA
‚Ä¢ Polyarticular JIA

Page 36:
Juvenile Idiopathic 
Arthritis (JIA)
‚ó¶ Most common rheumatologic disease of 
childhood
‚ó¶ Includes a heterogenous group of 
inflammatory arthritides*
‚ó¶ Characterized by a chronic inflammatory 
arthritis 
‚ó¶ Disease onset: before 16 years of age
36
*International League of Associations of Rheumatology (ILAR) classification criteria
Medinformer

Page 37:
Systemic JIA 
Arthritis in one or more joints and fever of at least 2 weeks‚Äô duration
Fever: at least 3 days of a quotidian pattern (rising once a day, then normalizing); plus, 
one more of the following features: 
‚Ä¢ Evanescent erythematous rash (see picture)
‚Ä¢ Most prominent when child is febrile; fades as the temperature returns to 
normal
‚Ä¢ Generalized lymphadenopathy 
‚Ä¢ Hepatomegaly/splenomegaly
‚Ä¢ Serositis
37UpToDate, Inc.
Salmon-pink, macular rash

Page 38:
Oligoarticular JIA
‚ó¶Most common subtype
‚ó¶ ‚â§ 4 peripheral joints involved at diagnosis
‚ó¶May extend to involve more joints after the first six months of illness 
‚ó¶ Clinical Presentation: 
‚ó¶ Typical patient: female toddler limping without complaint (‚Äúwalks funny‚Äù)
‚ó¶ Joints (e.g., knees, ankles): tend to be asymmetric, swollen, tender, warm, no 
erythema

Page 39:
Polyarticular JIA
‚ó¶> 4 affected joints during the first six months of illness
‚ó¶ Further categorized as being RF positive or RF negative 
‚ó¶Clinical Presentation: joint involvement is symmetric
‚ó¶Young children (< 10 years of age): more indolent course
‚ó¶Older children and adolescents: more rapid onset of inflammation in 
multiple joints

Page 40:
COMPARING 
JIA 
SUBTYPES
2025 UpToDate, Table 
modified
Features of JIA 
subtypes 
Systemic Oligoarticular Polyarticular
% of JIA patients 10-15 50 30-40
Sex F=M F>M F>M
Age Any <17 Peaks 2-3, rare >10 Peaks 2-5, 10-14 
Joints Any 
number/any 
joint
‚â§ ùüí large joints 
5 or more joints, 
usually symmetric
Fever, rash, 
lymphadenopathy, 
hepatosplenomegaly
Yes No No
Uveitis Rare ANA+ ANA+
Elevated ESR
Elevated
Normal or mildly 
elevated
Elevated
ANA
Negative + low titer common
+ low titer common 
in younger
RF Negative Negative +/-
Treatment 
NSAIDs, 
DMARDs, 
glucocorticoids
Intraarticular 
glucocorticoids, 
NSAIDs, rarely 
DMARDs
DMARDs, NSAIDs, 
PT/OT, 
glucocorticoids

Page 41:
OSTEOARTHRITIS

Page 42:
Osteoarthritis (OA)
‚ó¶ Most common form of arthritis 
‚ó¶ Substantial morbidity associated with 
OA
‚ó¶ Disability/reduced quality of life
‚ó¶ Incidence increases with age (~50 
years of age)
‚ó¶ Higher in females compared with 
males

Page 43:
OA: 
Joint Involvement
‚ó¶ Single- or multiple-joint OA 
‚ó¶ Predilection for: 
‚ó¶ 1st CMC joints, IP joints
‚ó¶Hips
‚ó¶ Knees
‚ó¶ Spine: Cervical and lumbar
‚ó¶ Feet: 1st MTP joints

Page 44:
OA: 
Multiple 
Risk Factors
44
Age (one of the strongest predictors of OA)
Female sex
Genetics
Joint injury (posttraumatic OA)
Anatomical factors (joint shape and alignment)
Lifestyle factors: obesity, occupation

Page 45:
Pathogenesis of OA
‚ó¶ Biochemical breakdown of articular 
cartilage in the synovial joints
‚ó¶ All joint tissues are involved
‚ó¶ Cartilage
‚ó¶ Synovium
‚ó¶ Bone
‚ó¶ Ligaments
45https://en.wikipedia.org/wiki/Joint_capsule

Page 46:
Joint Changes in OA
‚ó¶Progressive loss and destruction of cartilage
‚ó¶Over time, joint space narrows
‚ó¶ Synovium
‚ó¶ Inflamed synovial membrane
‚ó¶ Bony changes of the joint
‚ó¶Marginal osteophytes (bone spurs) 
‚ó¶ Subchondral bone thickening, cysts
‚ó¶ Soft-tissues
‚ó¶ Thickening of the joint capsule, tears in ligaments
‚ó¶ Periarticular muscles and nerves are also affected 
by OA resulting in weakness and pain 
46https://en.wikipedia.org/wiki/Joint_capsule

Page 47:
47
ResearchGate

Page 48:
OSTEOARTHRITIS
Characteristic Features

Page 49:
Primary Symptoms of OA
49
JOINT PAIN STIFFNESS LOSS OF MOBILITY

Page 50:
OA: 
Differential 
Diagnosis
50
Rheumatoid arthritis (RA)
Gout and pseudogout
Avascular necrosis (femoral head)
Greater trochanter pain syndrome 
(i.e., trochanteric bursitis)
Not an all-inclusive list

Page 51:
OA: Joint Pain 
and Stiffness
‚ó¶ Joint pain 
‚ó¶ Insidious onset, slow progression over years
‚ó¶ Worse with joint use (usage-related pain)
‚ó¶ Relieved by rest
‚ó¶ Night pain in severe OA
‚ó¶ Stiffness of the joint, if present (short-lived, < 30 minutes)
‚ó¶ Typically, worse after any effort/often described as 
evening stiffness
‚ó¶ May have morning-or inactivity-related stiffness

Page 52:
Additional 
Signs and 
Symptoms
52
‚ó¶ Joint line tenderness
‚ó¶ Crepitus (a grating sensation)
‚ó¶ Reduced ROM
‚ó¶ Bony enlargement/swelling
‚ó¶ Joint deformity (advanced joint 
damage)
‚ó¶ Instability

Page 53:
OA: Hands
‚ó¶Heberden nodes (DIP)
‚ó¶Bouchard nodes (PIP)
‚ó¶1st carpometacarpal joint (CMC)
‚ó¶Often ‚Äúsquared‚Äù off

Page 54:
OA: Knees
‚ó¶Swelling/effusions
‚ó¶Joint line tenderness
‚ó¶Crepitus
‚ó¶Limitation of ROM
54
Swollen left knee with varus and fixed flexion deformity. On palpation there was 
marked crepitus, restricted flexion, bony swelling, and a small effusion. UpToDate

Page 55:
OA: Hips
‚ó¶Restricted internal ROM
‚ó¶Pain around the 
hip/groin
‚ó¶May have referred pain 
to the knee (distal)
55
UpToDate
Right hip OA, showing painful restriction with internal rotation in flexion

Page 56:
Radiological 
Changes in OA
‚ó¶Joint space narrowing 
‚ó¶Marginal osteophytes
‚ó¶Subchondral sclerosis, 
cysts
56
UptoDate

Page 57:
Radiological Changes in OA: 
Weight-Bearing Imaging is Key
57
UptoDate; https://www.ahcmedia.com/ext/resources/newsletters/e/EMR/2015/05/figure-1-radiograph.jpg

Page 58:
Laboratory 
Findings
58
‚ó¶ Negative RF & anti-CCP antibodies
‚ó¶ Normal ESR and CRP
‚ó¶ Synovial fluid analysis
‚ó¶ May be helpful to r/o other 
disease processes
‚ó¶ CBC
‚ó¶ Typically, no leukocytosis

Page 59:
Clinical 
Diagnosis of 
OA
59
Supported by: 
‚ó¶ Presence of typical signs and symptoms in 
the at-risk age group
‚ó¶ Persistent usage-related joint pain in 
one or few joints
‚ó¶ Morning stiffness ‚â§ 30 minutes
‚ó¶ Age ‚â• 45 years

Page 60:
TREATMENT
Aimed at Improving Pain and Function

Page 61:
Management 
in OA
61
‚ó¶ Patient education
‚ó¶ To include targeting modifiable risk 
factors, self-management skills
‚ó¶ Common OA-related conditions:
‚ó¶ Depression, sleep disturbances, etc.
‚ó¶ Nonpharmacologic therapy
‚ó¶ Exercise programs, weight 
management, PT/OT, assistive devices 
(when needed)
‚ó¶ Pharmacologic therapy
‚ó¶ Treating pain and inflammation

Page 62:
Pharmacologic Treatment for OA*
‚ó¶NSAIDs (topical or oral)
‚ó¶ Topical capsaicin
‚ó¶Duloxetine (Cymbalta)
‚ó¶ Intraarticular glucocorticoids, hyaluronic acid, platelet-rich plasma (PRP) 
‚ó¶Others: glucosamine, chondroitin
62
*Guidelines vary: American College of Rheumatology (ACR), European League Against Rheumatism (ELAR), American Academy of 
Orthopaedic Surgeons (AAOS)

Page 63:
Surgical Treatment for OA
63
Medscapestatic.com
Total joint replacement (hip and knee arthroplasty):
‚Ä¢ Reserved for those who failed less invasive 
modes of therapy

Page 64:
OA: Summary
64
‚ó¶ Usage-related pain, relieved with rest
‚ó¶ Brief, short-lived [morning] stiffness (<30 
minutes)
‚ó¶ Heberden‚Äôs nodes/Bouchard‚Äôs nodes
‚ó¶ 1st CMC joint
‚ó¶ Crepitus, joint line tenderness, decreased ROM
‚ó¶ Osteophytes
‚ó¶ Treatment: NSAIDs (topical/oral) vs. other

Page 65:
65
Feature RA OA
Clinical Manifestations 4 S‚Äôs: symmetrical, small joints, 
synovitis, and systemic
LOAD: large joints, oligoarticular, 
asymmetric, and degenerative
Primary joints affected
MCP, PIP DIP, 1st CMC
Joint Characteristics
Soft, warm, and tender Hard and bony
AM stiffness
+++ +
Aggravating Sxs
Rest Activity
Alleviating Sxs
Activity Rest
RA vs. OA- Know the Differences
UptoDate, table modified; DiBaise 2021, Giannelli 2018

Page 66:
66

Page 67:
POLYMYALGIA 
RHEUMATICA 
(PMR)

Page 68:
Polymyalgia 
Rheumatica 
(PMR): 
Overview
‚ó¶ Relatively common, chronic inflammatory rheumatic 
condition of unknown etiology
‚ó¶ Characterized clinically by aching and morning stiffness 
of the shoulders, neck, & pelvic girdle
‚ó¶ Strong association with giant cell arteritis (GCA)
‚ó¶ Predominately those > 50 years of age
‚ó¶ Prevalence increases progressively with advancing age
‚ó¶ Women are affected 2-3x more often than men
‚ó¶ Annual incidence is highest in Scandinavian countries 
and in people of northern European descent

Page 69:
PMR: 
Cause is 
Unknown
‚ó¶ An autoimmune process may play a role in PMR
‚ó¶ Genetic predisposition (HLA types)
‚ó¶ Possible environmental factors (i.e., virus ?)
‚ó¶ The muscle in PMR is histopathologically normal
‚ó¶ The symptoms of PMR result from inflammation of 
the joint and surrounding tissues (bursae and 
tendons): 
‚ó¶ Example: Bilateral subdeltoid/subacromial bursitis 
(imaging hallmark of PMR)

Page 70:
PMR: Clinical Presentation
‚ó¶ Often, a recent, discrete change in sx
‚ó¶ Bilateral shoulder pain (nearly all patients)
‚ó¶ Neck and pelvic girdle pain (50 to 70%)
‚ó¶ Morning stiffness (>1 hr)
‚ó¶ Stiffness with prolonged inactivity (gel 
phenomenon)
‚ó¶ Functional limitations (ADLs)
‚ó¶ Systemic symptoms
‚ó¶ Malaise, fatigue, low-grade fever

Page 71:
PMR: Physical Examination
‚ó¶ Limited (restricted) ROM
‚ó¶ Limitation of active abduction of 
shoulders is common
‚ó¶ Normal muscle strength
‚ó¶ Subjective weakness
‚ó¶ Clinical synovitis at the peripheral joints

Page 72:
PMR: 
Differential Diagnosis
72
DDx for PMR
Inflammatory Conditions
‚Ä¢ Seronegative RA (older adults)
‚Ä¢ Late-onset seronegative 
spondyloarthropathy
‚Ä¢ Myositis
‚Ä¢ Systemic lupus erythematosus (SLE)
‚Ä¢ Other vasculitis 
‚Ä¢ CPPD disease (pseudogout)
‚Ä¢ Active infection
Noninflammatory Conditions
‚Ä¢ Fibromyalgia
‚Ä¢ Bilateral rotator cuff syndrome
‚Ä¢ Bilateral adhesive capsulitis
‚Ä¢ OA of the cervical spine and shoulders
UpToDate, Inc. Table modified

Page 73:
PMR: Diagnostic Studies
‚ó¶ Elevated ESR and/or CRP
‚ó¶ ESR frequently > 40 mm/hr, but can exceed 100 mm/hr
‚ó¶Negative ANA, RF, anti-CCP antibodies
‚ó¶CBC: may see indicators of inflammation 
‚ó¶Creatine kinase (CK) is normal
‚ó¶ Imaging may be helpful (not required) if there is diagnostic uncertainty
‚ó¶MRI and ultrasound to confirm presence of bursitis/tenosynovitis

Page 74:
PMR: 
Clinical 
Diagnosis
No established diagnostic criteria
‚ó¶Age 50 years or older at disease onset
‚ó¶Bilateral shoulder and/or pelvic girdle pain
‚ó¶Morning stiffness (lasting longer than 45 
min) 
‚ó¶Duration > 2 weeks
‚ó¶ Elevated ESR and/or CRP
‚ó¶Prompt response of symptoms to low-dose 
glucocorticoids (e.g., prednisone)

Page 75:
Initial Treatment 
for PMR
‚ó¶ Low-dose prednisone (e.g., 10-20 
mg/day)
‚ó¶ Subsequently, the dose is gradually 
reduced
‚ó¶ Most require some dose of 
prednisone for a minimum of 1 year
75Source: UpToDate

Page 76:
Summary: PMR
‚ó¶ Inflammatory rheumatologic condition of unknown etiology 
‚ó¶Bilateral aching and morning stiffness: shoulders, hip/pelvic girdle, neck
‚ó¶Association with GCA
‚ó¶Almost exclusively a disease of adults over the age of 50
‚ó¶More common in women
‚ó¶ Elevated ESR/CRP
‚ó¶ Initial treatment: Glucocorticoids (e.g., prednisone)

Page 77:
FIBROMYALGIA 
(FM)

Page 78:
Fibromyalgia (FM)
‚ó¶ Most common cause of generalized, musculoskeletal pain in women; ages 20 to 55 
‚ó¶ Characterized by chronic widespread pain (CWP) (also termed multisite pain (MSP))
‚ó¶ Often accompanied by fatigue, cognitive disturbance, psychiatric symptoms, and 
multiple somatic symptoms
‚ó¶ Often co-occurs with other rheumatic conditions: RA and SLE, for example

Page 79:
Fibromyalgia: 
Etiology unknown;
Pathophysiology uncertain
79
Currently understood to be a disorder of pain regulation/altered pain processing
Characterized by central sensitization syndrome
Augmented pain response to normally non-painful stimuli
Strong genetic predisposition

Page 80:
80
MEDSCAPE
? altered gut 
microbiome

Page 81:
Fibromyalgia: Clinical Manifestations
81
Chronic widespread pain
‚ÄúI hurt all over‚Äù
‚ÄúFeels like I always have the flu‚Äù
Fatigue and sleep disturbances
Wakes up feeling unrefreshed, even after 
> 8 hrs of sleep
Cognitive disturbances ‚Äúfibro fog‚Äù
Psychiatric disturbances Depression and/or anxiety
Other symptoms/disorders
Paresthesia‚Äôs, sensitivity to noises, light, 
odors, cold

Page 82:
Additional 
Symptoms/Disorders 
Associated with 
Fibromyalgia
82
Headache
Irritable bowel syndrome (IBS)
Chronic fatigue syndrome (CFS)
Pelvic pain 
Interstitial Cystitis (IC)/ painful bladder syndrome
Obstructive sleep apnea (OSA)
Restless legs syndrome (RLS)

Page 83:
83
Medscape

Page 84:
Fibromyalgia:
Differential 
Diagnosis
84
Rheumatoid arthritis (RA)
Systemic lupus erythematosus (SLE)
Polymyalgia rheumatica (PMR)
Polymyositis
Spondyloarthritis (SpA)
Lyme disease
Hypothyroidism
Neuropathies
Myofascial pain syndromes
Iron deficiency anemia

Page 85:
Fibromyalgia: 
Physical Exam 
and 
Diagnostics 
85
‚ó¶ Estimate tenderness with palpation in 
multiple soft tissue sites
‚ó¶ No soft tissue or joint swelling or redness
‚ó¶ FM itself does not cause any abnormalities 
in routine laboratory testing or imaging
‚ó¶ Evaluate for other coexisting conditions
‚ó¶ CBC, ESR/CRP baseline
‚ó¶ Select cases: ANA/RF, TSH, CK, sleep 
study

Page 86:
Physical Exam:  
Assess widespread 
muscle and soft 
tissue tenderness, 
bilaterally, below 
and above the waist
86
Source: UpToDate

Page 87:
FIBROMYALGIA: 
SYMPTOM-
BASED 
DIAGNOSIS
UpToDate, Table, modified
87
History Physical Exam
Laboratory 
Tests
Chronic (‚â• 3 
months)
Widespread 
(multisite) tenderness
Normal 
ESR/CRP
Normal CBCWidespread pain Absence of joint 
swelling, 
inflammation
Fatigue, sleep 
disturbances
Other symptoms: 
cognitive 
disturbances, 
headaches, bowel 
irritability
See Resources for 
additional guidance on 
Diagnostic Criteria

Page 88:
Treatment 
for 
Fibromyalgia
88
Multidisciplinary 
approach 
Shared decision-
making
Patient preference
Symptoms
Comorbidities 
SDOH
Nonpharmacologic 
therapy
Pharmacologic 
therapy

Page 89:
Nonpharmacologic 
Treatment For FM
‚ó¶Patient education is key!
‚ó¶Exercise program
‚ó¶Physical therapy
‚ó¶Sleep hygiene 
‚ó¶Cognitive behavioral therapy (CBT)
‚ó¶Mindfulness

Page 90:
Fibromyalgia: Pharmacologic Treatment
Initial therapy for most patients: start with a low dose tricyclic antidepressant at nighttime
‚ó¶ Amitriptyline (eg, 5-10mg po qhs)
Other options for select patients: 
‚ó¶ Serotonin-norepinephrine reuptake inhibitors (SNRIs)
‚ó¶ Helpful for prominent fatigue or depression
‚ó¶ Examples: duloxetine (cymbalta)* or milnacipran (savella)*
‚ó¶ Anticonvulsants
‚ó¶ Helpful for prominent sleep disturbance
‚ó¶ Examples: pregabalin (lyrica)* or gabapentin (neurontin)
90 *FDA approved

Page 91:
91
Stepwise Fibromyalgia Therapy
Confirm the diagnosis
Patient Education
‚Ä¢Regarding the condition, prognosis, cognitive therapy, role of exercise
Evaluate and treat comorbidities, such as mood and sleep disturbances
-Most patients: 
Trial with low-dose tricyclic antidepressants or selected antidepressants or anticonvulsants proven effective in fibromyalgia
Exercise program, PT, Psychological interventions/cognitive behavioral therapy
Multidisciplinary programs
-Patients not responding to above: 
Specialty referral (eg, rheumatologist, physiatrist, psychiatrist, pain management)
Combinations of drug therapies Table, modified from UpToDate

Page 92:
92
‚Ä¢ Bilateral shoulder and hips
‚Ä¢ Morning stiffness > 1 hr
‚Ä¢ Glucocorticoids
‚Ä¢ Chronic widespread pain 
‚Ä¢ Fatigue, sleep 
disturbances
‚Ä¢ Amitriptyline 
‚Ä¢ 1st CMC, DIP
‚Ä¢ Usage-related pain 
‚Ä¢ NSAIDs 
‚Ä¢ MCP, PIP (spares DIP)
‚Ä¢ Morning Stiffness > 1hr
‚Ä¢ Methotrexate
RA OA
Polymyalgia 
rheumatica
Fibromyalgia

Page 93:
RESOURCES AND 
REFERENCES

Page 94:
DMARDs
Not an all-inclusive list 
*Biosimilars available
94
DMARDs Notes
Nonbiologic (synthetic, traditional, conventional) 
‚Ä¢ Methotrexate 
‚Ä¢ Sulfasalazine
‚Ä¢ Leflunomide
‚Ä¢ Hydroxychloroquine
‚Ä¢ Generally recommended as first-line
Biologic 
TNF-Inhibitors:
‚Ä¢ Etanercept (Enbrel)*
‚Ä¢ Infliximab (Remicade)*
‚Ä¢ Adalimumab (Humira)*
Non-TNF-Inhibitors:
‚Ä¢ Rituximab (Rituxan)*
‚Ä¢ Abatacept (Orencia)
‚Ä¢ Tocilizumab (Acetemra)
Targeted synthetic: JAK inhibitor
Tofacitinib (Xeljanz), etc.

Page 95:
Treat-to-Target Strategy
‚ó¶Systematic approach, frequent 
monitoring of disease activity (using 
validated instruments), modification of 
treatment to minimize disease activity 
with a goal of a predefined target (low 
disease activity or remission)

Page 96:
RA: 
ASSESSMENT OF 
DISEASE ACTIVITY
UpToDate

Page 97:
AMERICAN 
COLLEGE OF 
RHEUMATOLOGY:
 
PRELIMINARY 
DIAGNOSTIC CRITERIA 
FOR FIBROMYALGIA
97
UPTODATE

Page 98:
QUESTIONS?

Page 99:
References
‚ó¶ CURRENT Diagnosis and Treatment 2023, 2024, 2025
‚ó¶ CURRENT Diagnosis and Treatment, Rheumatology, 2021
‚ó¶ Wasserman A. Rheumatoid arthritis: Common questions about diagnosis and management. Am Fam Phys. 2018; 97(7): 455-462.
‚ó¶ UpToDate
‚ó¶ Medscape
‚ó¶ American College of Rheumatology (ACR)
‚ó¶ Coffey CM, et al. Evidence of diagnostic and treatment delay in seronegative rheumatoid arthritis: missing the window of opportunity. Mayo Clin 
Proc. 2019; 94(11): 2241-2248.
‚ó¶ 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis 
‚ó¶ DiBaise M, Kohn S. Diagnosing and managing patients with rheumatoid arthritis. JAAPA. 2021; 34(5): 27-34.
‚ó¶ Sasek C. An update on primary care management of knee osteoarthritis. JAAPA. 2015; 28(1): 37-43.
‚ó¶ American Academy of Orthopaedic Surgeons Management of Osteoarthritis of the Knee (Non- Arthroplasty) Evidence-Based Clinical Practice 
Guideline. https://www.aaos.org/OAK3CPG. Published 08/30/2021. 
‚ó¶ Rheumatology for the PCP. Understanding the Basics of Degen/Autoimmune Syndromes: OA, RA, Psoriatic Arthritis (PsA), Systemic Lupus 
Erythematosis (SLE). Antonio Giannelli MsA, PA-C, DFAAPA. 2019 AAPA Conference. Denver, Co.

Page 100:
References
‚ó¶ Advances In the Diagnosis and Treatment of Rheumatoid Arthritis. Benjamin J Smith, MPAS, PA-C, DFAAPA. 2019 AAPA 
Conference. Denver, Co. 
‚ó¶ Rheumatology 101. Understanding the Basics of Degen/Autoimmune Syndromes: OA, RA, Ankylosing Spondylitis (AS), 
SLE. Antonio Giannelli MsA, PA-C, DFAAPA. 2018 AAPA Conference.
‚ó¶ Chen D, Shen J, Zhao W, et al. Osteoarthritis: toward a comprehensive understanding of pathological mechanism. Bone 
Res. 2017;5:16044
‚ó¶ Pisetsky DS. Advances in the treatment of rheumatoid arthritis: costs and challenges. N C Med J. 2017; 78(5): 337-340.
‚ó¶ Sekhon LJ. Usin gth enew ACR criteria for early diagnosis of rheumatoid arthritis. JAAPA. 2011; 24(10): 32-36.
‚ó¶ Smith BJ, Nuccio BC, Graves KY, McMillan VM. Preparing patients for biologic medications for dermatologic and 
rheumatic diseases. JAAPA. 2018; 31(6): 23-28.
‚ó¶ Gonz√°lez-Gay MA, Matteson EL ,Casta√±eda S. Polymyalgia rheumatica. Lancet. 2017; 390 : 1700-12. 
‚ó¶ Clauw DJ, et al. Normalizing fibromyalgia as a chronic illness. Postgrad Med J. 2018; 130 (1): 9-18.